

Key Recommendations and Practical Guidance for Performing and Reporting Validation Studies according to the 2019 Universal Standard for the Validation of Blood Pressure Measuring Devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO)

Short title: Blood pressure monitors validation

George Stergiou¹, Paolo Palatini², Roland Asmar³, John P. Ioannidis⁴, Anastasios Kollias¹, Peter Lacy⁵, Richard J McManus⁶, Martin Myers⁷, Gianfranco Parati⁸, Andrew Shennan⁹, Jiguang Wang¹⁰, Eoin O'Brien¹¹, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring

¹Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece.

²Department of Medicine. University of Padova, Italy.

³Foundation, Medical Research Institutes, Paris France.

⁴Departments of Medicine, of Health Research and Policy, and of Biomedical Data Science, Stanford University School of Medicine, and Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, USA.

⁵Institute of Cardiovascular Science, University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, UK.

⁶Green Templeton College, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

⁷University of Toronto, Schulich Heart Program. Division of Cardiology, Sunnybrook Health Sciences Centre, Toronto, Canada.

⁸Department of Medicine and Surgery, University of Milano-Bicocca; Istituto Auxologico Italiano, IRCCS, Cardiology Unit and Department of Cardiovascular, Neural and Metabolic Sciences, S.Luca Hospital, Milano, Italy.

⁹Department of Women and Children's Health, School of Life Course Sciences, FoLSM, Kings College, London, UK.

¹⁰Shanghai Institute of Hypertension, Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

¹¹The Conway Institute, University College Dublin, Ireland.

Source of funding: none

Conflict of interest: GS, PP, RA, GP, EOB: conducted validation studies for various manufacturers; advised manufacturers on device and software development. RM: Received blood pressure monitoring equipment for research purposes from Omron and Lloyds Pharmacies; Chair of British Hypertension Society Blood Pressure Monitoring Working Party which oversees validation studies for various manufacturers. AS: Conducted validation studies for various manufacturers; developed the CRADLE VSA. JW: Conducted validation studies for various manufacturers. JJ, AK, PL, MM: none.

Word count: Abstract: 157 Manuscript: 4,304 (with references)
Tables: 8 **Figures:** 2 **Suppl. files:** 1

Correspondence: Prof. George S. Stergiou,
Hypertension Center STRIDE-7,
National and Kapodistrian University of Athens, School of Medicine,
Third Department of Medicine, Sotiria Hospital.
152 Mesogion Avenue, Athens 11527, Greece.
Tel: +30 2107763117, Fax: +30 2107719981
Email: gstergi@med.uoa.gr

Abstract

In the last 30 years several organizations have developed protocols for clinical validation of blood pressure measuring devices. An international initiative was recently launched by the US Association for the Advancement of Medical Instrumentation (AAMI), the European Society of Hypertension Working Group on Blood Pressure Monitoring (ESH) and the International Organization for Standardization (ISO), aiming to reach consensus on a universal AAMI/ESH/ISO validation standard. The purpose of this statement by the ESH Working Group on Blood Pressure Monitoring is to provide practical guidance for investigators performing validation studies according to the AAMI/ESH/ISO Universal Standard, to ensure that its stipulations are meticulously implemented and data are fully reported. Thus, this statement provides: (i) a list of key recommendations for validation studies of intermittent non-invasive automated blood pressure measuring devices according to the AAMI/ESH/ISO Universal Standard, (ii) practical stepwise guidance for researchers performing these validation studies, (iii) a checklist for authors and reviewers of such studies.

Keywords: accuracy, blood pressure measurement, device, monitor, protocol, standard, validation

Background

Documenting the accuracy of blood pressure (BP) measuring devices is fundamental for the reliable diagnosis and efficient management of hypertension and other medical conditions. In the last 30 years, several organizations such as the US Association for the Advancement of Medical Instrumentation (AAMI), the British Hypertension Society, the European Society of Hypertension (ESH) Working Group on BP Monitoring, the German Hypertension League and the International Organization for Standardization (ISO), have put considerable effort into establishing minimum standards of accuracy and performance for BP monitors [1,2].

In 2016, an international initiative was launched by the AAMI, the ESH and the ISO, with the purpose of drawing on past experience to achieve consensus on a universal validation procedure [3]. In 2018, an AAMI/ESH/ISO statement was published presenting the global principles and key elements of such a protocol, and stipulating that it would replace all previous ones [3]. Since then, the AAMI/ESH/ISO Universal Standard for the validation of BP measuring devices has been completed and is available at the ISO (www.iso.org/standard) [4] and the American National Standards Institute websites (webstore.ansi.org) [5]. The AAMI, ESH and ISO membership comprises medical doctors with expertise in BP monitoring research, methodologists, and technical staff from medical device manufacturers all of whom worked together over many months to reach consensus on this Universal Standard for the validation of BP measuring devices [3]. To allow for completion and publication of ongoing validation studies using previous protocols, the AAMI/ESH/ISO Universal Standard will be implemented as the mandatory international standard for BP measuring devices one year after the date of its publication.

The ESH Working Group on BP Monitoring has a long history of developing validation procedures for worldwide use and in providing guidance for investigators in the accurate implementation and complete reporting of BP monitor validation studies [6-8]. With the establishment and publication of the Universal Standard, it is important to provide practical guidance for investigators performing validation studies to ensure that its stipulations are meticulously implemented and data are fully reported.

The purpose of this statement from the ESH Working Group on BP Monitoring is to deliver:

- (i) a list of all the key recommendations for validation studies of intermittent non-invasive automated BP measuring devices according to the AAMI/ESH/ISO Universal Standard,
- (ii) a practical stepwise guidance for researchers performing such validation studies and
- (iii) a checklist for authors and reviewers of these validation studies to ensure complete data reporting according to the AAMI/ESH/ISO Universal Standard.

It is not the purpose of this statement to discuss the rationale and supporting evidence for the requirements included in the AAMI/ESH/ISO Universal Standard, nor to present information on the mathematical and statistical background and formulae used for its calculations; these details are available in the 2019 ISO and AAMI publications [4,5]. Likewise, considerations of the opposite arm simultaneous method of validation, the use of reference invasive BP, the additional requirements for devices intended for ambulatory monitoring or exercise stress testing and validations in children aged <3 years are not discussed in this paper but are included in the 2019 ISO and AAMI publications [4,5]. This standard is not appropriate for validating continuous cuffless BP monitors or central BP monitors for which other validation procedures will be developed [3].

Validation study registration

- Transparency in the process of evaluating the accuracy of BP monitors is essential. Prospective registration of validation studies should become mandatory for devices that have been brought to the market to ensure that those that failed validation are not recommended and withdrawn, even when the validation results are not published. The investigators and manufacturers should be encouraged to share the raw data of validation studies.

Validation team

- **Observers:** Two (or more) health-care professionals trained in auscultatory BP measurement will be qualified for their accuracy against an expert observer and against each other immediately before the validation study initiation using the following procedure: 10 BP measurements are made by the observers simultaneously and blinded to each-other's readings (two Y-tube connected auscultatory devices [see below 'Reference BP measurement - Devices'] with single inflation system; dual-head stethoscope; deflation rate 2-3 mmHg/s; Korotkoff K1 for systolic [SBP] and K5 for diastolic BP [DBP]) on each of 5 subjects (total of 50 measurements) with a BP range from 110/60 to 190/110 mmHg [9]. Forty-five of the resulting SBP and DBP differences between observers must be ≤ 5 mmHg and 48 differences ≤ 10 mmHg [9]. Failure to achieve this level of agreement necessitates repeat training of the observers and re-assessment. If disagreement persists audiograms will be performed.
- **Supervisor:** An individual experienced in validation protocols must supervise the entire validation procedure, including assessing the adequacy of reference and test device BP measurements and taking the BP measurements with the test device.

Validation procedure

- **Conditions:** The validation study must be performed in an isolated and quiet room at a comfortable temperature for the individual participant. The validation procedure starts with the subject seated comfortably and relaxed for at least 5 min, her/his back and arm supported with the middle of the upper arm at heart level, legs uncrossed and feet flat on the floor. The subject will be asked to empty his/her bladder prior to the validation session. Talking and any other interference must be avoided throughout the entire validation procedure.
- **Procedure:** The same arm sequential BP measurement method is the recommended standard for validation (Table 1) [2-6,9]. The opposite arm simultaneous method can also be used as presented in the 2019 Universal Standard [4,5]. With the sequential method either arm may be used. One of the 2 observers' records the subject's heart rate (also checks for potential arrhythmia) and a Reference BP measurement ($R0$) is taken simultaneously by the two observers (see below 'Reference BP measurement'). Then the cuff is changed and a Test device measurement ($T0$) is taken (Table 1). Then 4 Reference BP measurements follow ($R1-R4$), alternated by 3 Test device measurements ($R1-T1-R2-T2-R3-T3-R4$). Measurements are performed with 60-s intervals from the change of the cuff to the start of the next reading.

Reference BP measurement

- **Method:** The auscultatory method is used for reference BP with measurements taken simultaneously by two trained observers (two Y-tube connected devices with single inflation system; cuff on bare arm; dual-head stethoscope) blinded to the readings of each-other and of the test device. The average of the 2 observers' measurements is the reference BP. Korotkoff K1 is used for reference SBP and K5 for DBP (deflation rate 2-3 mmHg/s) in all subjects (adults, children aged ≥ 3 years, pregnancy). If K1 or K5 is not audible, the subject is excluded. Parallax errors, terminal digit preference and rounding must be avoided.

- Devices: Mercury sphygmomanometers **must be** calibrated at the beginning of each validation study. Nonmercury auscultatory manometers (aneroid or other) that fulfill the ISO 81060-1 requirements and with maximum permissible error ± 1 mmHg can also be used [3-5]. The accuracy of non-mercury devices must be evaluated against a mercury sphygmomanometer or a calibrated and certified pressure device at the beginning of each validation study. National metrology institutes and other institutions might provide such calibration services. The reference device type, manufacturer and calibration must be reported.
- Cuffs: The cuffs used for reference auscultatory BP measurement must have an inflatable bladder length that covers 75-100% of the upper arm circumference of each subject and width that covers 37-50% of the arm circumference [3]. The arm circumference must be measured at the upper arm midpoint (marking the arm posteriorly at a point halfway between the highest [acromion] and lowest bony point [olecranon]) while the arm is hanging freely by the side. An example of cuff use (inflatable bladder dimensions) for reference auscultatory BP measurement in a general population validation study including children is shown in **Table 2**. The test device cuffs must not be used for reference BP measurements. The inflatable bladder dimensions of the cuffs used for reference BP measurement must be reported.
- Observer agreement: The supervisor will review each pair of Reference/Test BP measurements **WHEN? See FDIS line 347**. If any of them needs to be excluded (due to observer disagreement >4 mmHg in simultaneous SBP or DBP measurement, or due to test device failure), then the exclusions must be documented and additional pairs of BP readings will be taken as necessary to complete 3 valid pairs of Reference/Test BP comparisons. A maximum total of 8 pairs of Reference/Test BP readings can be taken (5 additional ones) until 3 valid pairs are obtained. Examples of observer disagreement and repeat pairs of measurements required are shown in **Figure 1**. The agreement between the observers during the validation study must be reported (mean difference, SD and range, number of measurements with disagreement).
- Reference BP variability: Subjects with SBP difference >12 mmHg and/or DBP >8 mmHg in any 2 of the 4 Reference (average of two observers) BP measurements *R1* to *R4* must be excluded. Measurement *R0* will not be used in the evaluation of reference BP variability.

Test device BP measurement

- The test device and cuffs must be used according to the manufacturer's instructions following a period of familiarization of the supervisor with the device function. Any issues in test BP measurements must be reported.

Validation studies in general and special populations

- General population studies: Requirements are presented in **Table 3**.
- Special populations studies: These are defined as subjects for whom there is theoretical and clinical evidence of different accuracy of BP monitors to that in the general population. At the present these include: (i) age <3 years; (ii) pregnancy including preeclampsia (see below); (iii) arm circumference >42 cm; (iv) atrial fibrillation (there is no agreed reference BP measurement and validation procedure for patients with atrial fibrillation). Subjects aged 12-18 or >80 years, patients with end-stage renal disease or peripheral artery disease, **or diabetes** with organ damage are possible special groups, but there is uncertainty on the adequacy of existing data suggesting altered accuracy of BP monitors and more research is needed. Requirements for validation studies in special populations are presented in **Table 4**.
- Children (age 3-12 years): Requirements are presented in **Table 5**.
- Pregnancy (including preeclampsia): Requirements are presented in **Table 6**.

Validation data analysis - Pass/fail criteria

- The validation data analysis is performed using the Reference BP measurements *R1-R4* and the Test device measurements *T1-T3*. Each of the Reference BP measurements is the average of the simultaneous readings of the two observers. Measurements *R0* and *T0* are not used in the evaluation of the test device accuracy.
- Each of the Test device measurements is compared against the average of the previous and succeeding Reference BP readings (e.g. *T1* versus the average of *R1-R2*, *T2* versus average of *R2-R3*, *T3* versus average of *R3-R4*). Differences are calculated by subtracting the Reference (*R*) BP measurement from the Test (*T*) device measurement. Thus, in an 85-subject study there are 255 paired BP comparisons.
- Standardized Bland-Altman scatterplots of the Test-Reference BP differences against their average value, which give a visual presentation of the raw data, must be provided as in **Suppl. Figure 1** (x-axis in SBP range 80-190 mmHg and DBP 30-140 mmHg; y-axes with errors from -30 to +30 mmHg for SBP and DBP plots); horizontal reference lines at 5 mmHg intervals from +15 to -15 mmHg; vertical lines to represent BP distribution boundaries; BP differences >30 mmHg plotted at point 30 mmHg and <-30 mmHg at -30 mmHg [3,6].
- For a device to pass the AAMI/ESH/ISO Universal Standard two criteria must be fulfilled:
 - a. *Criterion 1 (for individual BP readings)*: The mean BP difference (Test minus Reference BP for all 255 pairs of measurements) must be ≤ 5 mmHg and its SD ≤ 8 mmHg for SBP and DBP (classic AAMI criterion [3-5,10]).
 - b. *Criterion 2 (for individual subjects)*: the SD of 85 averaged BP differences (Test minus Reference BP per subject) must be within a threshold defined by the mean Test-Reference BP difference listed in **Table 7** for SBP and DBP [3-5].

Validation study data reports

For the optimal execution and data reporting of validation studies according to the 2019 AAMI/ESH/ISO Universal Standard the following tools are provided:

- a. Forms for the supervisor and observers of validation studies for compiling individual subjects' data while performing a study (**Figure 2**).
- b. Checklist for investigators of validation studies and for reviewers of validation study papers submitted for publication in scientific journals or other peer review organizations (**Table 8**).
- c. Example of full paper reporting a validation study with complete results, tables and figure (see end of article).

The above tools aim to prevent protocol violations in performing validation studies and incomplete data reporting (missing or unclear data), which are particularly common and often missed by the peer-review process of scientific journals [7,11-13].

Acknowledgments

We thank validation team members in Athens, London, Oxford, Padova and Paris for helping in the development of practical tools for performing and reporting a validation study.

References

1. O'Brien E, Dolan E, Stergiou GS. Achieving reliable blood pressure measurements in clinical practice: It's time to meet the challenge. *J Clin Hypertens* 2018;20:1084-1088.
2. Stergiou GS, Alpert BS, Mieke S, Wang J, O'Brien E. Validation protocols for blood pressure measuring devices in the 21st century. *J Clin Hypertens* 2018;20:1096-1099.
3. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, Frick G, Friedman B, Graßl T, Ichikawa T, Ioannidis JP, Lacy P, McManus R, Murray A, Myers M, Palatini P, Parati G, Quinn D, Sarkis J, Shennan A, Usuda T, Wang J, Wu CO, O'Brien E. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. *J Hypertens*. 2018;36:472-478.
4. ISO-2019 – webstore.ansi.org – In press.
5. AANS/AAMI – www.iso.org/standard – In press.
6. O'Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, Imai Y, Wang J, Mengden T, Shennan A; Working Group on Blood Pressure Monitoring of the European Society of Hypertension. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. *Blood Press Monit*. 2010;15:23-38.
7. Stergiou GS, Karpettas N, Atkins N, O'Brien E. European Society of Hypertension International Protocol for the validation of blood pressure monitors: a critical review of its application and rationale for revision. *Blood Press Monit*. 2010;15:39-48.
8. Stergiou GS, Asmar R, Myers M, Palatini P, Parati G, Shennan A, Wang J, O'Brien E; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Improving the accuracy of blood pressure measurement: the influence of the European Society of Hypertension International Protocol (ESH-IP) for the validation of blood pressure measuring devices and future perspectives. *J Hypertens*. 2018;36:479-487.
9. O'Brien E, Petrie J, Littler WA, de Swiet M, Padfield PL, Altman D, et al. The British Hypertension Society Protocol for the evaluation of blood pressure measuring devices. *J Hypertens* 1993; 11(Suppl 2):S43-S62.
10. Association for the Advancement of Medical Instrumentation. The National Standard of Electronic or Automated Sphygmomanometers. Arlington, VA: AAMI; 1987.
11. Hodgkinson JA, Sheppard JP, Heneghan C, Martin U, Mant J, Roberts N, McManus RJ. Accuracy of ambulatory blood pressure monitors: a systematic review of validation studies. *J Hypertens*. 2013;31:239-250.
12. Boubouchairopoulou N, Kollias A, Atkins N, O'Brien E, Stergiou GS. Validation of blood pressure monitors using the AAMI and ISO protocols: an overview of their recent application. European Society of Hypertension 26th Meeting (Abstract). *J Hypertens*. 2016;34:e286.
13. McManus R, Lacy P, Clark C, Chapman N, Lewis P; British and Irish Hypertension Society Blood Pressure Measurement Working Party. Reporting of blood pressure monitor validation studies. *Blood Press Monit*. 2018;23:214-215.

Table 1.

Standard procedure for reference and test device BP measurements in same arm sequential validation method (with permission from [3]).

Initial BP measurements*	
1. Take Reference BP measurement by the 2 observers	<i>R0</i>
2. Take Test device BP measurement	<i>T0</i>
Validation BP measurements for accuracy evaluation	
3. Take 1st Reference BP measurement by the 2 observers	<i>R1</i>
4. Take 1st Test device BP measurement	<i>T1</i>
5. Take 2nd Reference BP measurement by the 2 observers	<i>R2</i>
6. Take 2nd Test device BP measurement	<i>T2</i>
7. Take 3rd Reference BP measurement by the 2 observers	<i>R3</i>
8. Take 3rd Test device BP measurement	<i>T3</i>
9. Take 4th Reference BP measurement by the 2 observers	<i>R4</i>

BP, blood pressure; * Measurement *R0* shall not be used in the evaluation of Reference BP distribution and variability criteria. Measurements *R0* and *T0* shall not be used in the evaluation of the test device accuracy.

Table 2.

Example of cuff use (inflatable bladder dimensions) for reference auscultatory blood pressure measurement in a general population validation study including children (with permission from [3]).

Bladder dimensions	Participant's mid-arm circumference (cm)					
	12-15	15-18	18-23	23-28	28-35	33-42
Length (cm)	12	15	18	23	28	33
Width (cm)	6	7	9	12	14	16

Table 3.

Requirements for a validation study in general population.

Sample size	At least 85 consecutive subjects fulfilling the standard requirements providing at least 255 paired (test and reference) BP measurements.
Age	>12 years
Gender	≥30% men and ≥30% women
Treatment	Untreated or treated
Exclusion criteria	Special populations (see below), presence of any arrhythmia and any issues during the validation procedure. Excluded subjects must be reported with reasons for exclusion.
Reference BP distribution criteria (readings <i>R1-R4</i>)	<ul style="list-style-type: none"> • Of the SBP readings ≥5% must be ≤100 mmHg, ≥5% must be ≥160 mmHg and ≥20% ≥140 mmHg. • Of the DBP readings ≥5% must be ≤60 mmHg, ≥5% must be ≥100 mmHg and ≥20% ≥85 mmHg. • Measurement <i>R0</i> shall not be used in the evaluation of reference BP distribution criteria.
Cuff sizes stratified subgroups	<ul style="list-style-type: none"> • For test devices with a single cuff ≥40% of the subjects must have arm circumference within the upper half of the specified range of use of the cuff, ≥40% within the lower half, ≥20% within the higher quarter, ≥20% within the lower quarter, ≥10% within the higher octal and ≥10% within the lower octal of the specified range of use of the cuff. • For test devices that have multiple (n) cuffs, each cuff must be tested on at least 1/(2 x n) of the subjects (e.g. in a 85-subject study, for a device with 2 cuffs ≥21 subjects per cuff and for 3 cuffs ≥14 subjects per cuff). For each test device cuff, ≥40% of the subjects included using this cuff must have arm circumference within the upper half of the specified range of use of the cuff and ≥40% within the lower half. • The mean test-reference BP difference and SD per cuff subgroup must be reported (these are not pass/fail criteria for the test device).

BP, blood pressure; SBP, systolic BP; DBP, diastolic BP; SD, standard deviation.

Table 4.

Requirements for validation studies in special populations.

Sample size	<ul style="list-style-type: none"> • At least 35 subjects to be investigated only after a full 85-subject general population study has been successfully completed. • At least 85 subjects for devices intended only for use in special population. • For children aged 3-12 years see table 5 and for pregnant women table 6.
Selection	<ul style="list-style-type: none"> • No gender, arm/cuff or Reference BP requirements.
Analysis	<ul style="list-style-type: none"> • Special population study data must be analyzed and reported independently of the general population study data. • For 85-subject special population studies both Criterion 1 and 2 apply. • For 35-subject studies after a full 85-subject general population study has been successfully completed both Criterion 1 and 2 apply → → → FDIS lines: 442,471.

Table 5.

Requirements for a validation study in children (age 3-12 years).

Sample size	<ul style="list-style-type: none"> • <i>Devices intended for children and older subjects:</i> 35 children aged 3-12 years can be included together with 50 subjects >12 years (the gender and BP distribution criteria to apply in the total 85-subject sample). • <i>Devices intended only for children:</i> ≥85 children aged 3-12 years are required. • <i>Devices with a special BP measurement mode for children:</i> ≥35 children aged 3-12 years are required (after a successful 85-subject study in general population; BP distribution requirements do not apply).
Reference BP	<ul style="list-style-type: none"> • Korotkoff K1 and K5 shall be used. If K1 or K5 are not audible, the child is excluded.
Analysis	<ul style="list-style-type: none"> • For 85-subject studies including 35 children and 50 older subjects, both the validation criteria 1 and 2 apply in the total 85-subject sample. Criterion 1 (Test minus Reference BP difference) must also be reported separately for children (not a pass/fail criterion). • For 85-children studies both the validation criteria 1 and 2 apply. • For a 35-children study of a device with a special BP measurement mode for children (performed after a successful study in general population) both the validation criteria 1 and 2 apply. → FDIS lines 233-235, 442-444, 471-473.

Table 6.

Requirements for a validation study in pregnancy including preeclampsia.

Sample size	<ul style="list-style-type: none"> • 45 pregnant women after a successful 85-subject study in general population (otherwise 85 pregnant women needed).
Selection criteria	<ul style="list-style-type: none"> • 15±1 normotensive women in second or third trimesters of pregnancy (BP <140/90 mmHg), 15±1 with hypertension in second or third trimesters of pregnancy (SBP ≥140 mmHg and/or DBP ≥90 mmHg without proteinuria), and 15±1 women with preeclampsia (SBP ≥140 mmHg and/or DBP ≥90 mmHg with proteinuria). • Arm/cuff and BP distribution criteria will not be applied.
Reference BP	<ul style="list-style-type: none"> • Korotkoff K1 and K5 shall be used. If K1 or K5 are not audible, the woman is excluded.
Analysis	<ul style="list-style-type: none"> • The mean Test minus Reference BP difference and its SD will be applied in the total 45 women sample as a pass/fail criterion for the test device in pregnancy (Criterion 1: mean BP ≤5 mmHg and SD ≤8 mmHg for SBP and DBP). • Data from preeclamptics (mean BP difference and SD) must be reported separately. This is not a pass/fail criterion.

Table 7.

Validation Criterion 2: Maximum permissible standard deviation for the 85 averaged blood pressure differences (test versus reference BP per subject) within a threshold defined by the mean difference (with **permission** from [10]).

Mean blood pressure difference	Maximum permissible standard deviation as function of the mean blood pressure difference (mmHg)									
	0.0	0.1	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9
± 0.	6.95	6.95	6.95	6.95	6.93	6.92	6.91	6.90	6.89	6.88
± 1.	6.87	6.86	6.84	6.82	6.80	6.78	6.76	6.73	6.71	6.68
± 2.	6.65	6.62	6.58	6.55	6.51	6.47	6.43	6.39	6.34	6.30
± 3.	6.25	6.20	6.14	6.09	6.03	5.97	5.89	5.83	5.77	5.70
± 4.	5.64	5.56	5.49	5.41	5.33	5.25	5.16	5.08	5.01	4.90
± 5.	4.79	—	—	—	—	—	—	—	—	—

Example: For mean ±4.2 mmHg the maximum permissible standard deviation is 5.49 mmHg (gray boxes).

TABLE 8. CHECKLIST FOR INVESTIGATORS AND REVIEWERS OF VALIDATION STUDIES PERFORMED USING THE 2019 AAMI/ESH/ISO UNIVERSAL STANDARD FOR THE VALIDATION OF BLOOD PRESSURE MEASURING DEVICES

European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability

		✓	NA	No
TITLE	Validation of the "manufacturer" "model" "measuring method" "type" blood pressure monitor for "use" in "population" according to the 2019 AAMI/ESH/ISO Universal Standard			1
ABSTRACT				
Objective	• Device (<i>manufacturer, model</i>)			2
	• Device measuring method (<i>oscillometric, auscultatory, aneroid, hybrid, other</i>)			3
	• Device type (<i>upper-arm, wrist, other</i>)			4
	• Device use (<i>home, office, ambulatory, other</i>)			5
	• Population (<i>general or special</i>)			6
	• Validation protocol			7
Methods	• Protocol (<i>2019 AAMI/ESH/ISO</i>)			8
	• Cuffs used for test device measurements (<i>number, arm circumferences</i>)			9
Results	• Recruited subjects (<i>number</i>)			10
	• Included subjects (<i>number</i>)			11
	• Criterion 1 for systolic and diastolic BP			12
	• Criterion 2 for systolic and diastolic BP			13
Conclusion	• Pass or Fail			14
	• Recommendation for specific clinical use			15
INTRODUCTION (<i>avoid unnecessary comments on BP measurement, device, and hypertension</i>)				
	• Device (<i>manufacturer, model</i>)			16
	• Device type (<i>oscillometric, auscultatory, aneroid, intra-arterial, other</i>)			17
	• Device use (<i>home, office, ambulatory, other</i>)			18
	• Device type (<i>upper-arm, wrist, other</i>)			19
	• Population (<i>general or special</i>)			20
	• Validation protocol			21
METHODS (<i>avoid detailed presentation of the Universal Standard</i>)				
	• Test device (<i>description, cuff sizes and recommended use</i>)			22
	• Participants (<i>sources of recruitment</i>)			23
	• Validation team			24
	• Reference blood pressure (<i>devices, cuffs with bladder dimensions</i>)			25
	• Procedure (<i>brief</i>)			26
	• Analysis (<i>brief</i>)			27
	• Study approval - Participants' consent			28
RESULTS				
	• Recruited subjects (<i>number</i>)			29
	• Included subjects (<i>number</i>) and excluded subjects (<i>number, reasons for exclusion</i>)			30
	• Participants' age, gender, arm (or wrist) circumference, entry BP R0 (<i>mean, SD, range</i>)			31
	• Requirements for sex, age, BP and cuff distribution (<i>tables</i>)			32
	• Observers' BP agreement (<i>mean difference, SD, range, number of readings with disagreement</i>)			33
	• Criterion 1 (<i>mean±SD</i>) for systolic and diastolic BP			34
	• Criterion 2 (<i>SD</i>) for systolic and diastolic BP			35
	• Criterion 1 (<i>mean±SD</i>) separately for each cuff (<i>not a pass/fail criterion</i>)			36
	• Criterion 1 (<i>mean±SD</i>) separately for 35 children or 15 preeclamptic women (<i>not a pass/fail criterion</i>)			37
	• Standardized Bland-Altman scatterplots of BP differences against their average value (SBP and DBP)			38
	• Investigators and manufacturers are encouraged to share the raw data of validation studies			
DISCUSSION (<i>avoid unnecessary comments on BP measurement, devices, and hypertension</i>)				
	• Pass or Fail			39
	• Recommendation for specific clinical use			40
CONFLICT OF INTEREST				
	• Funding of study - Provision of equipment - Other			41
REFERENCES (<i>avoid unnecessary references on general issues</i>)				
	• Protocol used (<i>2019 AAMI/ESH/ISO reference</i>)			42
	• Previous validation studies of the test device. Study limitations. Other relevant comments			43

Figure 1.

Examples of inter-observer reference (R) blood pressure measurements disagreement (black boxes) and repeat pairs (valid consequent R-T-R) of measurements required (dotted circles represent the R and test (T) device measurements to be discarded; max 8 pairs are allowed not including R0 and T0).




Figure 2.

Forms for supervisor and observers of validation studies to fill individual subjects' data while performing a study.

Supervisor		Date: ___/___/20___ Time: ___:___	Patient ID No
Supervisor's initials: _____ Patient's initials: _____ DOB: ___/___/___ Sex: _____ Arm circ: _____ cm Test device: _____ Test device cuff: _____ Reference device cuff (inflatable bladder dimensions): _____ X _____ cm			
Test device SBP/DBP measurements (mmHg)			
<div style="border: 1px solid black; padding: 2px; display: inline-block;">T0</div> <div style="margin-left: 10px;">_____/_____ PR: _____</div>	<div style="border: 1px solid black; padding: 2px; display: inline-block;">T1</div> <div style="margin-left: 10px;">_____/_____ _____/_____ _____/_____</div>	Notes	
Repeat measurements (if necessary)		T4 Repeat _____/_____ T5 Repeat _____/_____ T6 Repeat _____/_____ T7 Repeat _____/_____ T8 Repeat _____/_____	
Comments _____ _____ _____			
2019 AAMI/ESH/ISO Universal Standard for the Validation of Blood Pressure Measuring Devices European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability			

Observer A		Date: ___/___/20___ Time: ___:___	Patient ID No
Observer's initials: _____ Patient's initials: _____ Test device: _____ Ausc. BP R0: _____/_____/_____ mmHg PR: _____			
Repeat measurements (if necessary)		R1 _____/_____ R2 _____/_____ R3 _____/_____ R4 _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____	
2019 AAMI/ESH/ISO Universal Standard for the Validation of BPMD Devices ESH Working Group on BP Monitoring			

Observer B		Date: ___/___/20___ Time: ___:___	Patient ID No
Observer's initials: _____ Patient's initials: _____ Test device: _____ Ausc. BP R0: _____/_____/_____ mmHg			
Repeat measurements (if necessary)		R1 _____/_____ R2 _____/_____ R3 _____/_____ R4 _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____ Repeat _____/_____	
2019 AAMI/ESH/ISO Universal Standard for the Validation of BPMD Devices ESH Working Group on BP Monitoring			

Example of full paper reporting an 85-subject general population validation study of a blood pressure monitor according to the 2019 AAMI/ESH/ISO Universal Standard

European Society of Hypertension Working Group on Blood Pressure Monitoring

Title: Validation of the NovelBP-99HT oscillometric blood pressure monitor for professional office use in general population according to the 2019 AAMI/ESH/ISO Universal Standard.

ABSTRACT

Objective: To evaluate the accuracy of the NovelBP-99HT oscillometric upper-arm professional office blood pressure (BP) monitor in general population according to the 2019 Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Universal Standard.

Methods: Subjects were recruited to fulfil the age, gender, BP and cuff distribution criteria of the 2019 AAMI/ESH/ISO Universal Standard in general population using the same arm sequential BP measurement method. Two cuffs of the test device were used for arm circumference 22-32 (medium) and 32-42 cm (large).

Results: Ninety-one subjects were recruited and 85 were analyzed. For validation Criterion 1, the mean \pm SD of the differences between the test device and reference BP readings was -2.3 \pm 6.2/0.6 \pm 4.8 mmHg (systolic/diastolic). For Criterion 2, the SD of the averaged BP differences between the test device and reference BP per subject was 4.62/4.01 mmHg (systolic/diastolic).

Conclusions: The NovelBP-99HT professional office BP monitor fulfilled the requirements of the 2019 AAMI/ESH/ISO Universal Standard in general population and can be recommended for clinical use.

Keywords: accuracy, blood pressure measurement, validation, automated, oscillometric, office.

Conflict of interest: None for all authors.

Funding: The study was funded by NovelBP, London, UK.

INTRODUCTION

This study assessed the blood pressure (BP) measurement accuracy of the professional oscillometric upper-arm cuff device NovelBP-99HT (*NovelBP, London, UK*) developed for office BP measurement using the 2019 Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Universal Standard in general population [1].

METHODS

Test device

The NovelBP-99HT is an automated oscillometric upper-arm BP monitor developed for professional use in the office. The device has a medium size cuff for arm circumference 22-32 cm and a large cuff for arm 32-42 cm, which were used in the validation study according to the manufacturers' instructions. Two identical devices were provided by the manufacturer for the validation study together with a written declaration that they were standard production models. One of them was randomly selected for the validation procedure.

Participants

According to the 2019 AAMI/ESH/ISO Universal Standard, for a general population validation study of a BP monitor at least 85 subjects aged >12 years are required [1]. Subjects were recruited from patients attending the outpatient hypertension clinic and from hospital staff.

Validation team

The study was conducted by a supervisor and 2 trained observers who were experienced in BP measurement research and were standardized for their agreement in BP measurement before the study initiation [1].

Reference BP

Two connected (Y-tube) standard mercury sphygmomanometers (*Supermeter, Meditools, Chicago, USA*), which had been calibrated before the study initiation were used for simultaneous reference auscultatory BP measurements by two observers using a dual-head teaching stethoscope (*Doctor Educ 3, Cardiocare, Berlin, Germany*). Three cuffs with inflatable bladder dimensions 12X23, 14X28, 16X33 cm respectively were used so that the length would be at 75-100% of the individual participant's midarm circumference and the width at 37-50% [1].

Procedure

The same arm sequential method of the 2019 AAMI/ESH/ISO Universal Standard was applied [1], which includes 2 entry BP measurements (reference R0 and test device T0) followed by 4 reference measurements (R1, R2, R3, R4) taken alternately with 3 test device measurements (T1, T2, T3). All measurements were taken on the left arm. The observers were blinded to each other's readings and the test device results. The supervisor recorded the test device measurements and checked the observers' measurements. In case of disagreement between the observers, additional pairs of measurements were performed. A maximum of 8 pairs of BP determinations was allowed after which the subject was excluded.

Analysis

The 2019 AAMI/ESH/ISO Universal Standard requirements were strictly followed [1].

Study approval

The study protocol was approved by the hospital scientific committee. All participants signed informed consent for study participation.

RESULTS

Ninety-one individuals were recruited and 85 were analyzed. Reasons for exclusion are presented in **Table 1**. The participants' characteristics are presented in **Table 2**. The AAMI/ESH/ISO Universal Standard requirements for age, gender, BP and cuff distribution were fulfilled. The mean BP difference between the simultaneous observers' measurements was 0.3 ± 1.6 [SD]/ -0.2 ± 1.7 mmHg (systolic/diastolic, range -4 to 4 mmHg). There were 18 BP readings with inter-observer disagreement >4 mmHg.

The distribution of the reference BP measurements R1-R4 is presented in **Table 3**. The medium cuff of the test device was used in 43 subjects and the large in 42. Participants with arm circumference within the upper/lower half of the specified range of use of the medium cuff were 24/19 respectively (56/44%) and of the large cuff 17/25 (40/60%). The validation analysis is shown in **Table 4**. Both the Criteria 1 and 2 suggested 'pass' for systolic and diastolic BP. Criterion 1 results per cuff size are presented in **Table 5**. Standardized Bland-Altman scatterplots of the test-reference BP differences against their average are shown in **Figure 1**.

Table 1. Participants recruited and excluded from the analysis.

	Subjects
Recruited	91
Excluded	6
Reasons for exclusion	
- Reference BP variability ($>12/8$ mmHg for systolic/diastolic)	4
- K sounds not audible	1
- Talking during BP measurements	1
Analyzed	85

Table 2. Participants' characteristics (n=85).

	Mean \pm SD	Range
Age (years)	54.8 \pm 12.1	22-75
Gender (male/female)	45/40	-
Arm circumference (cm)	32.1 \pm 4.1	23.0-39.8
Entry SBP <i>RO</i> (mmHg)	129.7 \pm 18	82-174
Entry DBP <i>RO</i> (mmHg)	79.8 \pm 11.7	48-112

Table 3. Distribution of reference BP measurements (*R1-R4*).

SBP	≤ 100 mmHg 9.8%	≥ 160 mmHg 6.7%	≥ 140 mmHg 28.2%
DBP	≤ 60 mmHg 5.1%	≥ 100 mmHg 5.9%	≥ 85 mmHg 34.9%


Table 4. Validation study results.

	Pass requirement	Achieved SBP	DBP
Criterion 1 (255 BP pairs)			
Mean BP difference (mmHg)	≤ 5	-2.3	0.6
SD (mmHg)	≤ 8	6.2	4.8
		Pass	Pass
Criterion 2 (85 Subjects)			
SD (mmHg, SBP/DBP)	$\leq 6.55/6.91$	4.62	4.01
		Pass	Pass
Result		Pass	

Table 5. Test device cuff size distribution and results (criterion 1).

Test device cuff size	Participants (%)	Mean SBP difference \pm SD (mmHg)	Mean DBP difference \pm SD (mmHg)
Medium	43 (51)	-2.2 \pm 6.0	1.6 \pm 4.6
Large	42 (49)	-2.3 \pm 6.4	-0.4 \pm 4.9

Figure 1. Standardized Bland-Altman scatterplots of the Test-Reference BP differences against their average [1].



DISCUSSION

This study shows that NovelBP-99HT office BP monitor fulfils the accuracy criteria of the 2019 AAMI/ESH/ISO Universal Standard in a general population and can be recommended for clinical use.

REFERENCES

1. Stergiou G, Palatini P, Asmar R, Ioannidis JP, Kollias A, Lacy P, McManus R, Myers M, Parati G, Shennan A, Wang J, O'Brien E, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Key Recommendations and Practical Guidance for Performing and Reporting Validation Studies according to the 2019 Universal Standard for the Validation of Blood Pressure Measuring Devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). *J Hypertens* 2019; **XX**:XX-XX.